Organ Dysfunction
ASH sickle cell disease research priorities address pain, organ dysfunction, drug development
American Society of Hematology has issued new sickle cell disease research priorities, highlighting seven key focus areas for maximum impact and benefit to patients.
FDA approves second Niemann-Pick disease type C treatment
The FDA has approved Aqneursa as an oral treatment for neurological symptoms associated with Niemann-Pick disease type C, a rare genetic disease, in adults and children weighing at least 15 kg, according to a press release.
Ravulizumab improves kidney function in patients with atypical hemolytic uremic syndrome
Ravulizumab was successful in improving blood health, kidney function and quality of life while maintaining eGFR in pediatric and adult patients with atypical hemolytic uremic syndrome, according to published data.
Acetaminophen lowers acute respiratory distress syndrome development in sepsis
SAN DIEGO — Fewer patients with sepsis receiving acetaminophen vs. placebo developed acute respiratory distress syndrome, according to research presented at the American Thoracic Society International Conference.
Geriatric assessment in AML treatment selection may impact early mortality rates
SAN DIEGO — Personalizing treatment using both geriatric assessment and genetic profiling may decrease rates of early mortality among older patients with acute myeloid leukemia, according to a study from ASH Annual Meeting and Exposition.
Dapagliflozin fails to prevent organ damage, death in adults hospitalized with COVID-19
Top-line data from the phase 3 DARE-19 trial show that the SGLT2 inhibitor dapagliflozin failed to prevent organ dysfunction and all-cause mortality among hospitalized patients with COVID-19 at risk for developing serious complications.